Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement

MT Newswires Live03-03

Roivant Sciences' (ROIV) subsidiary Genevant Sciences and Arbutus Biopharma (ABUS) said Monday they have filed five international lawsuits seeking to enforce patents protecting their lipid nanoparticle technology against infringement by Moderna and certain affiliates.

The enforcement actions target alleged infringing activities in 30 countries, the two companies said. They are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna products that allegedly use the same technology, including mRESVIA.

Lawsuits were filed in courts in Canada, Japan and Switzerland, while two were filed in the European Union's Unified Patent Court.

The enforcement actions expand on the two companies' ongoing enforcement proceeding in the US District Court for the District of Delaware, seeking fair compensation for Moderna's alleged infringement of six US patents in the manufacture and sale of Spikevax. A jury trial is currently scheduled for September, they said.

Moderna did not immediately respond to a request for comment from MT Newswires.

Price: 10.44, Change: -0.30, Percent Change: -2.79

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2516637517?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-03 23:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516637517","market":"us","top_or_hot":-1,"title":"Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement","media":"MT Newswires Live","content":"<html><body><p> Roivant Sciences' (ROIV) subsidiary Genevant Sciences and Arbutus Biopharma (ABUS) said Monday they have filed five international lawsuits seeking to enforce patents protecting their lipid nanoparticle technology against infringement by Moderna and certain affiliates.</p><p>The enforcement actions target alleged infringing activities in 30 countries, the two companies said. They are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna products that allegedly use the same technology, including mRESVIA.</p><p>Lawsuits were filed in courts in Canada, Japan and Switzerland, while two were filed in the European Union's Unified Patent Court.</p><p>The enforcement actions expand on the two companies' ongoing enforcement proceeding in the US District Court for the District of Delaware, seeking fair compensation for Moderna's alleged infringement of six US patents in the manufacture and sale of Spikevax. A jury trial is currently scheduled for September, they said.</p><p>Moderna did not immediately respond to a request for comment from MT Newswires.</p><p>Price: 10.44, Change: -0.30, Percent Change: -2.79</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-03 23:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Roivant Sciences' (ROIV) subsidiary Genevant Sciences and Arbutus Biopharma (ABUS) said Monday they have filed five international lawsuits seeking to enforce patents protecting their lipid nanoparticle technology against infringement by Moderna and certain affiliates.</p><p>The enforcement actions target alleged infringing activities in 30 countries, the two companies said. They are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna products that allegedly use the same technology, including mRESVIA.</p><p>Lawsuits were filed in courts in Canada, Japan and Switzerland, while two were filed in the European Union's Unified Patent Court.</p><p>The enforcement actions expand on the two companies' ongoing enforcement proceeding in the US District Court for the District of Delaware, seeking fair compensation for Moderna's alleged infringement of six US patents in the manufacture and sale of Spikevax. A jury trial is currently scheduled for September, they said.</p><p>Moderna did not immediately respond to a request for comment from MT Newswires.</p><p>Price: 10.44, Change: -0.30, Percent Change: -2.79</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2516637517","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516637517","pubTimestamp":1741014467,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Roivant Sciences'  subsidiary Genevant Sciences and Arbutus Biopharma  said Monday they have filed five international lawsuits seeking to enforce patents protecting their lipid nanoparticle technology against infringement by Moderna and certain affiliates.The enforcement actions target alleged infringing activities in 30 countries, the two companies said. They are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna products that allegedly use the same technology, including mRESVIA.Lawsuits were filed in courts in Canada, Japan and Switzerland, while two were filed in the European Union's Unified Patent Court.The enforcement actions expand on the two companies' ongoing enforcement proceeding in the US District Court for the District of Delaware, seeking fair compensation for Moderna's alleged infringement of six US patents in the manufacture and sale of Spikevax. A jury trial is currently scheduled for September, they said.Moderna did not i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4585":"ETF&股票定投概念","ABUS":"Arbutus Biopharma Corporation","BK4501":"段永平概念","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4588":"碎股","ROIV":"Roivant Sciences Ltd.","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓"},"translate_title":"Roivant Sciences部门Arbutus对Moderna提起专利侵权诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABUS":0.9,"ROIV":0.9},"content_text":"Roivant Sciences' (ROIV) subsidiary Genevant Sciences and Arbutus Biopharma (ABUS) said Monday they have filed five international lawsuits seeking to enforce patents protecting their lipid nanoparticle technology against infringement by Moderna and certain affiliates.The enforcement actions target alleged infringing activities in 30 countries, the two companies said. They are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna products that allegedly use the same technology, including mRESVIA.Lawsuits were filed in courts in Canada, Japan and Switzerland, while two were filed in the European Union's Unified Patent Court.The enforcement actions expand on the two companies' ongoing enforcement proceeding in the US District Court for the District of Delaware, seeking fair compensation for Moderna's alleged infringement of six US patents in the manufacture and sale of Spikevax. A jury trial is currently scheduled for September, they said.Moderna did not immediately respond to a request for comment from MT Newswires.Price: 10.44, Change: -0.30, Percent Change: -2.79","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2516637517"}